Advertisement

Primary Aldosteronism

  • Alejandro Raul AyalaEmail author
  • Mark Anthony Jara
Chapter
  • 93 Downloads

Abstract

This chapter will focus on primary Aldosteronism (the most common form of endocrine hypertension). Other causes of endocrine hypertension that include pheochromocytoma/paraganglioma syndromes, severe cases of hyperthyroidism and hypothyroidism, Cushing syndrome, hyperdeoxycorticosteronism, apparent mineralocorticoid excess syndrome, and acromegaly are reviewed elsewhere.

Keywords

Aldosterone Primary Aldosteronism Mineralocorticoid receptors 

Suggested Reading

  1. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Endocrine Society, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol. 2008;93(9):3266–81.  https://doi.org/10.1210/jc.2008-0104.CrossRefGoogle Scholar
  2. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metabol. 2016;101(5):1889–916.  https://doi.org/10.1210/jc.2015-4061.CrossRefGoogle Scholar
  3. Keuer B, Ayala AR, Pinto P. The role of intra- and postoperative serum aldosterone levels following adrenalectomy for primary aldosteronism. 64th Annual Meeting of the American Urologic Association (Mid-Atlantic Section), Washington, DC, October 12–15 2006.Google Scholar
  4. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40(6):897–902.CrossRefGoogle Scholar
  5. Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29(5):980–90.  https://doi.org/10.1097/HJH.0b013e3283455ca5.CrossRefPubMedGoogle Scholar
  6. Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60.  https://doi.org/10.1161/HYPERTENSIONAHA.113.02097.CrossRefPubMedGoogle Scholar
  7. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism. A controlled cross-sectional study. Hypertension. 2013;62(2):331–6.  https://doi.org/10.1161/HYPERTENSIONAHA.113.01060.CrossRefPubMedGoogle Scholar
  8. Stowasser M, Ahmed AH, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012;44(3):170–6.  https://doi.org/10.1055/s-0031-1295460.CrossRefPubMedGoogle Scholar
  9. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607–18.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of Miami, Miller School of Medicine, Department of Endocrinology and MetabolismMiamiUSA
  2. 2.University of Miami, Miller School of Medicine, Division of Endocrinology and MetabolismMiamiUSA

Personalised recommendations